SPECIAL REPORT: Can Innovation Supplant Convention in Sarcoidosis Treatment?
Decision Resources
September 23, 2009 24 Pages - SKU: DECR2444570
|
|
Introduction
"I'd love there to be a better agent," says a thought leader on the current state of sarcoidosis treatment. Many
sarcoidosis patients require little or no treatment, but patients with chronic disease need a therapy that is safer
than the corticosteroids that have become the mainstay treatment for the disease. Because substantial market
constraints have limited development in this therapeutic area, only a few novel agents are in the pipeline.
However, opportunity remains for an agent that can address some of the unmet needs in this market.
Questions Answered in This Report
Sarcoidosis is an infl ammatory disease that is hallmarked by - the development of granulomas. What organ
systems are affected by sarcoidosis? How is the disease diagnosed? What is the prognosis for patients
with sarcoidosis?
- Sarcoidosis affects only a small percentage of the population. How many people were hospitalized with
sarcoidosis in 2008? Is this population expected to grow?
- Patients with chronic sarcoidosis will require multiple treatment courses throughout their lifetime. What
are the current treatments for sarcoidosis? What are their benefi ts and drawbacks? How do emerging
treatments compare with current offerings?
- Reimbursement challenges loom large in this market. What effect are they having on sales? How might
companies overcome these challenges? What are the ideal characteristics of an agent positioned to
capture the sarcoidosis market?
Scope
- Overview of sarcoidosis: Pathophysiology and etiology, symptoms, diagnosis.
- Epidemiology: Decision Resources epidemiology analysis of the diagnosed incidence and the
number of patients hospitalized with sarcoidosis in the United States, 2008-2018.
- Current treatments: Corticosteroids, methotrexate, antimalarials, TNF-รก inhibitors.
- Emerging treatments: Celgene's apremilast, MondoBiotech/Biogen Idec's aviptadil, Centocor/
Medarex's Stelara, ongoing academic research.
- Market: 2008 sales, opportunities and challenges for emerging agents, remaining unmet need,
outlook for the sarcoidosis market.
- Primary research: Interviews with thought leaders in sarcoidosis.
Please note, the PDF e-mail from publisher version of this report is for a global site license.
|
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Introduction
- Overview of Sarcoidosis
- Symptoms
- Pathophysiology and Etiology
- Diagnosis
- Epidemiology
- Overview
- Disease Defi nition
- Methods
- Subpopulations
- Current Therapies
- Corticosteroids
- Methotrexate
- Antimalarials
- TNF-Alpha Inhibitors
- Other Treatments
- Emerging Therapies
- Academic Research
- Agents Seeking Approval for Sarcoidosis: Celgene’s Apremilast, Centocor/Medarex’s
- Stelara, and MondoBiotech/Biogen Idec’s Aviptadil
- Outlook
- Bibliography
- Tables
- 1. The Scadding Criteria for Sarcoidosis Staging
- 2. Current Therapies Used in the Treatment of Sarcoidosis
- 3. Academic- and Government-Initiated Clinical Trials in Sarcoidosis
- 4. Agents in Development for the Treatment of Sarcoidosis
- 5. Sales of Agents to Treat Sarcoidosis in the United States, 2008
- Figures
- 1. Granuloma Formation in Sarcoidosis
- 2. Diagnosed Incidence of Sarcoidosis in the United States, 2008-2018
Share this report
Other tasks Related Markets Research & Development Reports Free Alert Me service Receive bi-weekly email alerts on new market research Sign Up Today!
|
